Atzumi is an FDA-approved dihydroergotamine nasal powder for the acute treatment of migraine. It utilizes the Simple MucoAdhesive Release Technology platform, achieving rapid absorption and sustained plasma concentrations of DHE with low interpatient variability. FDA approval was supported by phase I pharmacokinetic study and ASCEND phase III trial, demonstrating its convenience and portability. However, Atzumi has warnings for serious adverse effects and is contraindicated in several conditions.

Source: Satsuma Pharmaceuticals